Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.

Petrillo A, Pappalardo A, Pompella L, Tirino G, Calabrese F, Laterza MM, Caterino M, Ventriglia A, Orditura M, Conzo G, Molino C, Ciardiello F, Biglietto M, De Vita F.

Med Oncol. 2019 Aug 23;36(10):83. doi: 10.1007/s12032-019-1306-9.

PMID:
31444639
2.

Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?

Ghidini M, Petrillo A, Salati M, Khakoo S, Varricchio A, Tomasello G, Grossi F, Petrelli F.

Cancers (Basel). 2019 Aug 1;11(8). pii: E1095. doi: 10.3390/cancers11081095. Review.

3.

TRPV2 Calcium Channel Gene Expression and Outcomes in Gastric Cancer Patients: A Clinically Relevant Association.

Zoppoli P, Calice G, Laurino S, Ruggieri V, La Rocca F, La Torre G, Ciuffi M, Amendola E, De Vita F, Petrillo A, Napolitano G, Falco G, Russi S.

J Clin Med. 2019 May 11;8(5). pii: E662. doi: 10.3390/jcm8050662.

4.

Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients.

Petrillo A, Laterza MM, Tirino G, Pompella L, Pappalardo A, Ventriglia J, Savastano B, Auricchio A, Orditura M, Ciardiello F, Galizia G, De Vita F.

J Gastrointest Oncol. 2019 Apr;10(2):314-323. doi: 10.21037/jgo.2018.12.06.

5.

Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions.

Petrillo A, Pompella L, Tirino G, Pappalardo A, Laterza MM, Caterino M, Orditura M, Ciardiello F, Lieto E, Galizia G, Castoro C, De Vita F.

Cancers (Basel). 2019 Mar 21;11(3). pii: E399. doi: 10.3390/cancers11030399. Review.

6.

Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer.

Bruixola G, Caballero J, Papaccio F, Petrillo A, Iranzo A, Civera M, Moriana M, Bosch N, Maroñas M, González I, Pastor M, Cervantes A.

ESMO Open. 2018 Oct 24;3(6):e000425. doi: 10.1136/esmoopen-2018-000425. eCollection 2018.

7.

What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives.

Tirino G, Pompella L, Petrillo A, Laterza MM, Pappalardo A, Caterino M, Orditura M, Ciardiello F, Galizia G, De Vita F.

Int J Mol Sci. 2018 Sep 7;19(9). pii: E2659. doi: 10.3390/ijms19092659. Review.

8.

Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.

Diana A, Franzese E, Centonze S, Carlino F, Della Corte CM, Ventriglia J, Petrillo A, De Vita F, Alfano R, Ciardiello F, Orditura M.

Curr Oncol Rep. 2018 Aug 20;20(10):76. doi: 10.1007/s11912-018-0726-6. Review.

PMID:
30128845
9.

Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy.

Petrillo A, Laterza MM, Tirino G, Pompella L, Ventriglia J, Pappalardo A, Famiglietti V, Martinelli E, Ciardiello F, Orditura M, Galizia G, De Vita F.

Future Oncol. 2018 Oct;14(24):2493-2505. doi: 10.2217/fon-2018-0167. Epub 2018 Jul 3.

PMID:
29969285
10.

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, Morano F, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F.

Target Oncol. 2018 Apr;13(2):227-234. doi: 10.1007/s11523-018-0562-5.

PMID:
29582224
11.

Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice.

Laterza MM, Pompella L, Petrillo A, Tirino G, Pappalardo A, Orditura M, Troiani T, Ciardiello F, Di Martino N, De Vita F.

Med Oncol. 2017 Oct 17;34(11):186. doi: 10.1007/s12032-017-1046-7.

PMID:
29043514
12.

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.

De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, Petrillo A, Diana A, Giordano G, Troiani T, Conzo G, Galizia G, Ciardiello F, Orditura M.

BMC Cancer. 2016 Sep 2;16(1):709. doi: 10.1186/s12885-016-2671-9.

13.

Pancreatic neuroendocrine tumors: Nosography, management and treatment.

Orditura M, Petrillo A, Ventriglia J, Diana A, Laterza MM, Fabozzi A, Savastano B, Franzese E, Conzo G, Santini L, Ciardiello F, De Vita F.

Int J Surg. 2016 Apr;28 Suppl 1:S156-62. doi: 10.1016/j.ijsu.2015.12.052. Epub 2015 Dec 18. Review.

14.

Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report.

Iovino F, Orditura M, Auriemma PP, Ciorra FR, Giordano G, Orabona C, Bara F, Sergio R, Savastano B, Fabozzi A, Laterza MM, Ventriglia J, Petrillo A, Della Corte CM, DE Vita F.

Oncol Lett. 2015 Mar;9(3):1403-1405. Epub 2014 Dec 23.

15.

Clinical management of advanced gastric cancer: the role of new molecular drugs.

De Vita F, Di Martino N, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V, Sforza V, Marano L, Auricchio A, Galizia G, Ciardiello F, Orditura M.

World J Gastroenterol. 2014 Oct 28;20(40):14537-58. doi: 10.3748/wjg.v20.i40.14537. Review.

Supplemental Content

Loading ...
Support Center